Palomar Medical to Debut New Devices and a More Powerful Platform at the American Academy of Dermatology Annual Meeting
07 3월 2009 - 12:00AM
PR Newswire (US)
BURLINGTON, Mass., March 6 /PRNewswire-FirstCall/ -- Palomar
Medical Technologies, Inc. (NASDAQ:PMTI), a leading researcher and
developer of light-based systems for cosmetic treatments, announced
today that it will unveil four new devices -- the XD Optic(TM), the
GROOVE Optic(TM), LuxPowR(TM) pulsed-light handpiece and a more
powerful Aspire SlimLipo(TM) Body Sculpting Laser at the 67th
Annual Meeting of the American Academy of Dermatology (AAD) in San
Francisco, California from March 7th to 9th. For use with the
StarLux(R) 500 laser and pulsed-light system, the new XD Optic
attaches to the Lux1440(TM) and Lux1540(TM) fractional non-ablative
laser handpieces, providing deeper skin resurfacing treatments.
While the Lux1440 and Lux1540 are known for fractional skin
resurfacing treatments, the easy-to-attach XD Optic provides deeper
columns of micro-damage. Palomar intends to seek FDA clearance for
this device in the near future and begin shipments upon clearance.
In addition, the GROOVE Optic, for use with the Lux2940(TM)
fractional ablative laser, provides lines of fractional ablation.
The Groove Optic offers results approaching the gold standard
full-surface ablation treatment but with the minimal downtime of a
fractional treatment. By changing the shape of the micro areas of
ablative damage from "dot" to "line", the pattern of treatment can
now be correlated with that of wrinkles. With multiple passes, a
faster, more uniform coverage can also be realized. The Lux2940 is
FDA cleared for skin resurfacing and treatment of wrinkles,
rhytides, furrows, fine lines, textural irregularities, pigmented
lesions, and vascular dyschromia. Palomar plans to begin shipments
of the GROOVE Optic this Spring. The LuxPowR intense pulsed-light
handpiece brings permanent hair reduction to a new level, without
sacrificing comfort. Capitalizing on the StarLux 500's increased
power and cooling, the LuxPowR's optical train generates fluence up
to a 100 J/cm2. An efficient cooling system and advanced optical
filtration are provided for patient comfort and safety. Palomar
plans to begin shipments of the powerful LuxPowR handpiece by this
Spring. The 40 Watt Aspire SlimLipo Body Sculpting Laser is the
premier member of the SlimLipo body sculpting family. With its high
continuous wave power output, optimized dual-wavelengths, and
superior treatment tip design, the 40 Watt system enables fast
treatment of larger volumes of fat. The SlimLipo laser-assisted
lipolysis device offers excellent results with minimal patient
downtime for true laser body sculpting. Palomar plans to begin
shipments of the more powerful SlimLipo in the coming weeks. Chief
Executive Officer Joseph P. Caruso commented, "Even in this
difficult economic environment, we continue to devote a large
percentage of our revenue to research and development in comparison
to others in our industry. The benefits of this investment are
shown in our current and new products, and we have protected this
investment through our intellectual property portfolio. We are
excited about our new products which represent Palomar's commitment
to continued research and improved science." Mr. Caruso continued,
"Several physicians are seeing fantastic results using a
combination therapy with the XD Optic on the Lux1440 or Lux1540
followed by the GROOVE Optic on the Lux2940. Some physicians
believe this combination therapy best addresses the unique needs of
the aging face - deep non-ablative resurfacing with the XD Optic
for excellent reduction in dyschromia and ablative resurfacing with
the GROOVE Optic for reduction of moderate lines and texture. Our
goal is to offer physicians multiple treatment options with the
fastest and most effective products. The new 40 Watt SlimLipo Body
Sculpting Laser represents that objective and will revolutionize
the laser-assisted liposuction industry." In addition to the
introduction of the XD Optic, the GROOVE Optic, LuxPowR pulsed
light handpiece and a more powerful Aspire SlimLipo Body Sculpting
Laser, the following presentations at AAD will be held in Palomar's
trade show booth: Saturday, March 7 -- 12:00pm - Combining Ablative
and Non-Ablative Fractional Handpieces for Maximum Results with
Minimum Downtime. -- 2:00pm - New Advancements in Fractional
Treatment of Scars. -- 3:00pm - True-Laser Lipolysis: The SLIM
Procedure(SM) (Selective Laser Induced Melting) Clinical
Experience. -- 4:00pm - Combining Ablative and Non-Ablative
Fractional Handpieces for Maximum Results with Minimum Downtime.
Sunday, March 8 -- 10:00am - Success with Lux2940(TM) Fractional
Ablation. -- 11:00am - Cross Selling Aesthetic Treatments with the
Beau Visage(TM) System. -- 1:00pm - True-Laser Lipolysis: The SLIM
Procedure(SM) (Selective Laser Induced Melting) Clinical
Experience. -- 2:00pm -Advanced Treatment Strategies in Hair
Reduction. -- 3:00pm - New Advancements in Fractional Treatment of
Scars. Monday, March 9 -- 10:00am - Cross Selling Aesthetic
Treatments with the Beau Visage(TM) System. -- 12:00pm - New
Advancements in Fractional Treatment of Scars. -- 2:00pm -
True-Laser Lipolysis: The SLIM Procedure(SM) (Selective Laser
Induced Melting) Clinical Experience. -- 3:00pm - Success with
Lux2940(TM) Fractional Ablation. Management will be available at
the AAD for investor demonstrations and to discuss Palomar's full
line of products in Booth # 2228 at the Moscone Center. To reserve
a time to meet with Palomar management and/or receive product
demonstrations, please contact Palomar's Investor Relations'
department at 781-993-2411 or . About Palomar Medical Technologies,
Inc.: Palomar is a leading researcher and developer of light-based
systems for cosmetic treatments. Palomar pioneered the optical hair
removal field, when, in 1997, it introduced the first high-powered
laser hair removal system. Since then, many of the major advances
in light-based hair removal have been based on Palomar technology.
In December 2006, Palomar became the first company to receive a
510(k) over-the-counter (OTC) clearance from the United States Food
and Drug Administration (FDA) for a new, patented, home use,
light-based hair removal device. OTC clearance allows the product
to be marketed and sold directly to consumers without a
prescription. There are now millions of light-based cosmetic
procedures performed around the world every year in physician
offices, clinics, spas and salons. Palomar is testing many new and
exciting applications to further advance the hair removal market
and other cosmetic applications. Palomar is focused on developing
proprietary light-based technology for introduction to the mass
markets. Palomar has granted The Procter & Gamble Company a
non-exclusive License Agreement to certain patents, technology and
FDA documents related to the home-use, light-based hair removal
field for women. In addition, Palomar has an exclusive development
and license agreement with Johnson & Johnson Consumer Companies
to develop and potentially commercialize home-use, light-based
devices for reducing or reshaping body fat including cellulite,
reducing the appearance of skin aging, and reducing or preventing
acne. For more information on Palomar and its products, visit
Palomar's website at http://www.palomarmedical.com/. To continue
receiving the most up-to-date information and latest news on
Palomar as it happens, sign up to receive automatic e-mail alerts
by going to the Investor Relations section of the website. This
press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements are based on the Company's current
expectations, plans, intentions, beliefs or predictions. These
forward-looking statements are neither promises nor guarantees, but
involve risk and uncertainties that may individually or mutually
impact the matters herein, and cause actual results, events and
performance to differ materially from such forward-looking
statements. These risk factors include, but are not limited to,
results of future operations, technological difficulties in
developing or introducing new products, the results of future
research, lack of product demand and market acceptance for current
and future products, the effect of economic conditions, challenges
in managing joint ventures and research with third parties and
government contracts, the impact of competitive products and
pricing, governmental regulations with respect to medical devices,
including whether FDA clearance will be obtained for future
products and additional applications, the results of litigation,
including patent infringement lawsuits, difficulties in collecting
royalties, potential infringement of third-party intellectual
property rights, factors affecting the Company's future income and
resulting ability to utilize its NOLs, and/or other factors, which
are detailed from time to time in the Company's SEC reports,
including the report on Form 10-K for the year ended December 31,
2008 and the Company's quarterly reports on Form 10-Q. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. The Company
undertakes no obligation to release publicly the result of any
revisions to these forward-looking statements that may be made to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events. Contact: Kayla Castle
Investor Relations Manager Palomar Medical Technologies Inc
781-993-2411 DATASOURCE: Palomar Medical Technologies, Inc.
CONTACT: Kayla Castle, Investor Relations Manager of Palomar
Medical Technologies Inc., +1-781-993-2411, Web Site:
http://www.palomarmedical.com/
Copyright
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Palomar Medical Technologies, Inc. (MM) (NASDAQ:PMTI)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024